Crossmark

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Crossref DOI link: https://doi.org/10.1007/s40744-022-00498-x

Published Online: 2022-10-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Combe, Bernard G. http://orcid.org/0000-0003-4002-1861
Tanaka, Yoshiya

Buch, Maya H.

Nash, Peter

Burmester, Gerd R.

Kivitz, Alan J.

Bartok, Beatrix

Pechonkina, Alena

Xia, Katrina

Emoto, Kahaku

Kano, Shungo

Hendrikx, Thijs K.

Landewé, Robert B. M.

Aletaha, Daniel
Funding

Funding for this research was provided by:

Gilead Sciences

Eisai Co., Ltd.

Gilead Sciences K.K.
License Information

Text and Data Mining valid from 2022-10-09

Version of Record valid from 2022-10-09
More Information

Article History

Received: 5 August 2022

Accepted: 16 September 2022

First Online: 9 October 2022

Change Date: 4 January 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40744-022-00530-0

Updates are available Correction dated 2023-01-04

Click to view Correction: https://doi.org/10.1007/s40744-022-00530-0